VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conferencetaking place April 20-21,
Continue Reading
Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce complement dependent cytotoxicity ProTECT™ (PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting), the first conditionally-active antibody technology that
Continue Reading
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR)
Continue Reading
Download the PDF version PDF Format (opens in new window) VANCOUVER, Canada--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a
Continue Reading
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.
Continue Reading
Download the PDF version PDF Format (opens in new window) James Priour promoted to Chief Commercial Officer, added to Zymeworks’ Executive Committee John Babcook recognized as Distinguished Fellow VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc.
Continue Reading
Active drug with multiple confirmed responses and stable disease observed in several tumor types Differentiated safety profile with the majority of adverse events being grade 1 or 2 Expansion cohorts open and enrolling patients at 2.5 mg/kg once every three weeks Maximum tolerated dose not
Continue Reading
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc.
Continue Reading
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities. “2020 was a leap forward for our lead clinical
Continue Reading
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39 th Annual J.P. Morgan Healthcare Conference.
Continue Reading
